Bank Of America Corp Tcr2 Therapeutics Inc. Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.0 - $1.62 $62,372 - $101,042	-62,372 Reduced 74.66%	21,166 $31,000
Q4 2022 Feb 10, 2023	SELL	$0.83 - $1.44 $29,157 - $50,585	-35,129 Reduced 29.6%	83,538 $83,000
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $35,855 - $72,288	-19,277 Reduced 13.97%	118,667 $213,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $2.94 $164,542 - $229,267	-77,982 Reduced 36.12%	137,944 $400,000
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $2.43 Million - $4.77 Million	-1,013,353 Reduced 82.43%	215,926 $596,000
Q4 2021 Feb 08, 2022	BUY	$4.58 - $8.34 $5.19 Million - $9.44 Million	1,132,206 Added 1166.34%	1,229,279 $5.73 Million
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $737,478 - $1.6 Million	87,379 Added 901.37%	97,073 $826,000
Q2 2021 Sep 13, 2021	BUY	$16.41 - $24.71 $159,078 - $239,538	9,694 New	9,694 $159,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.